셀룰래리티 (CELU) 주가

셀룰래리티(CELU)는 NASDAQ에 상장된 Healthcare · Biotechnology 기업입니다. 현재가 $0.70 (+0.07%), 시가총액 $0.03B, 52주 범위 $0.93 ~ $4.15.

Celularity Inc., a regenerative and cellular medicines company, focuses on addressing aging-related and degenerative diseases. It develops off-the-shelf placental-derived allogeneic cell therapy product candidates, including mesenchymal-like adherent stromal cells for diabetic foot ulcer and Crohn's disease. The company operates through three segments: Cell Therapy, Degenerative Disease, and BioBanking. Its therapeutic programs include PDA-001 for the treatment of autoimmune (Crohn's) and degenerative disease; and PDA-002 for treating facioscapulohumeral muscular dystrophy. The company is also developing pExo-001, a human postpartum placenta derived exosome product for the treatment of osteo

핵심 지표

• 현재가: $0.70 (+0.07%)
• 시가총액: $0.03B
• 52주 최저~최고: $0.93 ~ $4.15
• 섹터: Healthcare
• 산업: Biotechnology
• 거래소: NASDAQ

셀룰래리티의 재무제표, 목표주가, 기관투자자(13F) 보유 현황, 관련 뉴스는 BlackQuant에서 실시간으로 확인할 수 있습니다.

셀룰래리티 재무 요약

애널리스트 전망

• 투자의견 컨센서스: 4

핵심 재무비율 · 수익성 · 성장성

• PBR (주가순자산비율): 9.89
• 순이익률: 0.00%
• 영업이익률: -4.92%

자주 묻는 질문